Literature DB >> 19276815

Modified technique for frontal sinus obliteration using calvarial bone and Tisseel glue.

Gavin Chun-Wui Kang1, Karen Wei-Ee Sng, Andrew George Tay.   

Abstract

BACKGROUND: Frontal sinus obliteration is indicated in trauma and frontal sinus disease. We present our experience with a modified technique of frontal sinus obliteration.
METHODS: We reviewed the records of 17 patients who underwent frontal sinus obliteration with a combination of Tisseel fibrin glue (Baxter Healthcare Corporation, Deerfield, IL) and calvarial bone and describe our technique.
RESULTS: One female and 16 male patients (mean age, 36.6) underwent frontal sinus obliteration from 2001 to 2005. Traumatic fracture was the most common indication. The patients were followed up for a median of 15 months. There were no major complications. Postoperatively, one patient developed a localized frontal wound infection at 3 weeks; this resolved with debridement. At latest follow-up, all were free from local sinus complications, disease recurrence, headaches, or intracranial events.
CONCLUSIONS: The combined use of autogenous calvarial bone and Tisseel is suitable for frontal sinus obliteration. Our technique is associated with low donor site morbidity, avoids a separate donor surgical site, and has a low complication rate.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19276815     DOI: 10.1097/SCS.0b013e31819b9fa1

Source DB:  PubMed          Journal:  J Craniofac Surg        ISSN: 1049-2275            Impact factor:   1.046


  2 in total

1.  Frontal sinus obliteration with autologous calvarial bone graft: indications and results.

Authors:  Pierre Vironneau; André Coste; Virginie Prulière-Escabasse
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-03-08       Impact factor: 2.503

2.  Effect of fibrin glue on the healing efficacy of deproteinized bovine bone and autologous bone in critical-sized calvarial defects in rats.

Authors:  Chengwei Tu; Aisha Bajwa; Andi Shi; Gang Wu; Jingxiao Wang
Journal:  Clin Oral Investig       Date:  2022-01-29       Impact factor: 3.573

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.